Feb. 21 Quick Takes: Crossovers back Hemab in $135M series B

Weeks after Hemab ApS began dosing in its first clinical trial, the biotech has announced a $135 million series B round led by Access Biotechnology. Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity also participated, as did existing investors Novo Holdings, HealthCap and RA Capital Management. Last month, Hemab started a Phase I/II trial of HMB-001, a bispecific targeting Factor VIIa and TLT-1, to treat Glanzmann thrombasthenia. The company also expects to conduct a clinical study of HMB-VWF to treat von Willebrand disease. Access’ Dan Becker and Avoro’s Uya Chuluunbataar joined Hemab’s board. The biotech closed a $55 million series A round in 2021.

FDA has set an action date of Oct. 8 for an sNDA from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) covering Onpattro patisiran as a treatment for cardiomyopathy of ATTR amyloidosis. The company said the agency is planning an advisory committee meeting to discuss the application, the date of which is not yet disclosed. An approval would expand Onpattro’s label to an ATTR population that is 2.5-3x larger than the polyneuropathy segment for which it is already approved. The sNDA is based on data from the APOLLO-B study, which read out last August. ...